Pharma Fundamentals: Hold Times in Biopharmaceuticals

In the manufacturing of biological drug substances (DS) and drug products (DP), hold times play a critical role in ensuring product quality, safety, and regulatory compliance. Hold times refer to the maximum allowable duration during which intermediate materials, bulk substances, or final products can be held before proceeding to the next step in the manufacturing process. These durations must be scientifically justified and validated.

Hold time is a central but often underappreciated concept in biopharmaceutical manufacturing. It sits at the intersection of process engineering, product stability, microbiology, and regulatory compliance. This paper takes a structured explanation covering definition, scientific basis, regulatory expectations, validation approaches, and real-world examples.

Definition of Hold Times

In biopharmaceutical manufacturing, hold time (or process hold time) refers to the maximum allowable time that materials (e.g., intermediates, bulk drug substance, buffers, or equipment) can be stored under defined conditions without compromising quality.

Regulatory bodies, such as the European Medicines Agency (EMA) and the World Health Organization (WHO) define process hold times as the period during which materials “may be held under specified conditions and remain within defined specifications.” Hold time study is defined as a scientific evaluation determining how long a material can be held, while maintaining identity, purity, safety, and potency, specifically as follows:

• Hold time refers to the time during which a product, intermediate, or raw material is stored under specified conditions before it is processed to the next manufacturing stage.
• Total hold time is the entire duration a material (e.g., an intermediate or bulk substance) is held from the point of its manufacture to its final use or packaging, including all storage and in-process steps.
• In-process hold time specifically refers to the duration between processing steps, for example, the time between filtration and filling, or between chromatography and formulation. It is a subset of the total hold time and is particularly important in biologicals, where the stability of intermediates can be time- and temperature-sensitive.

Why Hold Time Is Critical in Biopharma

Biopharmaceutical products—including monoclonal antibodies (mAbs), vaccines, and advanced cell and gene therapies (CGTs)—are inherently complex molecules whose structural integrity is closely tied to their safety and efficacy. Unlike small-molecule drugs, these biologics are highly sensitive to environmental and processing conditions, making them particularly vulnerable to time-dependent degradation during manufacturing hold steps. Prolonged or poorly controlled holds can lead to chemical changes such as oxidation, deamidation, and aggregation, as well as physical instability including protein unfolding and precipitation. In addition, aqueous processing environments increase the risk of microbial contamination, while inconsistencies in hold conditions can introduce process variability that affects yield and downstream performance. For these reasons, establishing and validating appropriate hold times is a critical component of robust and compliant biologics manufacturing processes.

Biopharmaceuticals (e.g., mAbs, vaccines, CGTs) are structurally complex and inherently unstable, making them highly sensitive to time-dependent degradation.

Key Risks During Hold Time

During manufacturing hold steps, biopharmaceutical materials are exposed to a range of risks that can compromise their quality and performance. Chemical degradation pathways—such as oxidation, deamidation, and aggregation—can gradually alter molecular structure, while physical instability may lead to protein unfolding or precipitation, reducing biological activity. At the same time, the predominantly aqueous environments used in processing heighten the risk of microbial contamination if conditions are not carefully controlled. Variability introduced during these holds can further propagate through the process, affecting overall yield and the consistency of downstream operations. Taken together, these considerations underscore the importance of establishing and validating appropriate hold times as a fundamental requirement for ensuring the reliability and robustness of commercial biologics manufacturing, such as the following:

• Chemical degradation
  • Oxidation, deamidation, aggregation
• Physical instability
  • Protein unfolding, precipitation
• Microbial contamination
  • Especially in aqueous solutions
• Process variability
  • Impact on yield and downstream performance

Because of this, validated hold times are considered essential for commercial manufacturing of biologics.

Where Hold Times Occur in a Typical Bioprocess

Hold times are an inherent part of biopharmaceutical manufacturing and can arise at nearly every stage of the process, from upstream production to final distribution. Following cell culture, harvested material may await clarification, while downstream purification introduces additional holds, such as post-Protein A chromatography pools, viral inactivation steps, and ultrafiltration/diafiltration retentate storage. In drug product manufacturing, formulated bulk solutions may be held prior to filling, and filled vials may remain in storage before packaging. Even during logistics, delays can occur before materials enter the controlled cold chain. Each of these intervals represents a potential point of risk to product quality, and as such, regulatory authorities expect all hold points to be clearly identified, scientifically justified, and rigorously validated within the overall manufacturing strategy.

Hold times can occur at nearly every stage, as follows:

• Upstream
  • Cell culture harvest waiting for clarification
• Downstream purification
  • Post-Protein A chromatography pool
  • Viral inactivation (low pH hold)
  • Ultrafiltration (UF)/diafiltration (DF) retentate storage
• Drug product manufacturing
  • Formulated bulk before filling
  • Filled vials before packaging
• Logistics
  • Time before entering cold chain.

Regulators expect all these hold points to be identified, justified, and validated.

Scientific Basis of Hold Time

The scientific basis of hold time in biopharmaceutical manufacturing lies in the interplay between time-dependent degradation kinetics and the surrounding environmental conditions. As biologic products are held between process steps, their stability is influenced by key variables such as temperature—often the most critical factor—along with pH, light exposure, oxygen levels, and the nature of the container closure system. These conditions can directly impact critical quality attributes (CQAs), including aggregation and fragmentation profiles, the formation of charge variants, and overall product potency. Additionally, extended holds may increase the risk of bioburden and endotoxin accumulation. A thorough understanding of these factors is essential for defining scientifically justified hold times that ensure product integrity and consistency throughout manufacturing.

Hold time is governed by the following time-dependent degradation kinetics and environmental factors:

• Key variables
  • Temperature (most critical)
  • pH
  • Light exposure

• Oxygen levels
• Container closure system

• CQAs affected
  • Aggregation levels
  • Fragmentation
  • Charge variants
  • Potency
  • Bioburden and endotoxins.

During hold studies, samples are analyzed at multiple time points for these attributes.

Regulatory and Industry Guidance

Biopharmaceuticals are sensitive to environmental conditions and may degrade or lose potency if held too long. Therefore, hold times must be validated and supported by stability data. Regulatory authorities such as the FDA and EMA require manufacturers to establish, justify, and verify hold times through formal studies, as an example Table 1 depicts some known knowledge summary for drug substance manufacturing.

FDA guidance. According to the FDA’s Guidance for Industry–Process Validation: General Principles and Practices (2011),1 hold times must be validated during process qualification to demonstrate that materials held at specific stages retain their quality attributes.The document states, “Any time a manufacturing process is paused, the conditions and time must be justified by data demonstrating that product quality is not adversely affected.”

European Union guidelines. Annex 2 for Biologicals of EudraLex Volume 4 (EU Guidelines to Good Manufacturing Practice) states, “The maximum hold time for any in-process material should be defined based on knowledge of the product and supported by stability data.”2GMP Annex 15 of EudraLex specifies that time limits for storage of starting materials, intermediate and bulk products should be based on data that demonstrate no adverse impact on quality.3

International Council for Harmonisation (ICH) guidelines. ICH Q7 (GMP for APIs), states that hold time studies should be performed when necessary to verify that intermediate and bulk products meet acceptance criteria throughout storage.4ICH Q8(R2) states, “Hold times should be established based on a combination of development data and GMP experience, ensuring that product quality attributes are maintained.”5ICH Q1A(R2) (Stability Testing), focuses on final products; however, it implies that intermediate hold times must not adversely affect the final product's stability.6

Hold Time Validation

The objective of hold time validation is to establish maximum allowable hold time with scientific evidence.7A typical approach to study design is as follows:

• Use production-scale or representative batches
• Store material under defined conditions
• Sample at multiple time points (e.g., 0, 6, 12, 24, 48 hours, etc.)
• Analyze CQAs and microbiological parameters.

Validation demonstrates that no significant degradation occurs and product remains within specifications. Hold time validation involves the following:

• Designing studies under worst-case conditions (e.g., highest temperature within range, longest duration).
• Testing critical quality attributes (CQAs) such as potency, purity, appearance, pH, and microbial load at multiple time points.
• Establishing limits that ensure the product remains within specifications over the defined hold period.

Validation studies typically assess the following:

• Chemical stability (e.g., pH, potency, degradation products).
• Microbiological control (e.g., bioburden testing).
• Physical characteristics (e.g., viscosity, color, turbidity).

For example, a protein solution held between UF/DF and sterile filtration might be validated for up to 24 hours at 2–8 °C, with testing on aggregation and potency confirming stability.

Key Considerations

When establishing hold times and storage conditions, several key considerations ensure robustness and product quality. Worst-case conditions should be deliberately evaluated, including the longest anticipated hold time, the highest temperature the material may encounter, and the most sensitive material fraction, as these represent the greatest risk to stability. Equally important is a clear definition of time zero (T₀), which must be unambiguous—such as marking it at the end of collection or the start of pooling—to ensure consistency across studies. Scale also plays a critical role, because lab-scale results may not directly translate to manufacturing scale due to differences in equipment, volumes, and environmental exposure. A well-designed sampling strategy is necessary to capture both the earliest and latest material exposure, providing a complete picture of potential variability over time. Finally, a risk-based approach should guide validation efforts, recognizing that not all hold points carry the same level of risk; tools such as failure mode effects analysis (FMEA),8 combined with process knowledge and historical data, help prioritize focus where it matters most.

Hold Times in Pharmaceutical Manufacturing

The main objectives of establishing hold times in pharmaceutical manufacturing are to ensure consistency and reproducibility in product quality, to prevent microbial contamination or chemical degradation, and to comply with regulatory expectations.Hold time is not a single concept but rather spans multiple stages of manufacturing, each with distinct considerations.

Intermediate hold time refers to the period between unit operations, such as after chromatography and before filtration, for example when a protein eluate is held overnight prior to pooling.

Bulk hold time applies to the storage of the drug substance before formulation or fill-finish, often under controlled conditions such as 2–8 °C to maintain stability.

In-process hold time captures delays within active processing steps, such as pauses between filtration and chromatography, where material may be temporarily idle but still exposed to process conditions.

Clean hold time, in contrast, relates to equipment rather than product, defining how long cleaned equipment can remain unused before it must be re-cleaned, typically measured from the end of cleaning to the next use.

Buffer or media hold time addresses the stability of prepared solutions prior to use in manufacturing.

Broadly, these categories can also be grouped as intermediate hold time (between steps like granulation and compression), bulk product hold time (storage before packaging), and solution or suspension hold time (when materials such as APIs in solvent are held before further processing), highlighting the need to evaluate stability and risk at each stage.

Designing a Hold Time Study

Designing a hold time study requires a structured approach to ensure materials remain stable and within specification throughout storage or processing delays. Key considerations include sampling at predetermined intervals—such as 0, 24, 48, and 72 hours or longer depending on process needs—to capture any time-dependent changes.

Storage conditions should closely mimic actual manufacturing environments or reflect worst-case scenarios, including factors like temperature and humidity. Container compatibility is also critical, as the selected containers must not interact with or compromise the material’s stability.

In addition, appropriate testing parameters must be defined, encompassing physical, chemical, and microbiological attributes relevant to the specific stage of the product. Ultimately, the study must demonstrate that the material consistently meets established specifications over the designated hold time. For microbiological evaluation, particular emphasis is placed on both sterile and non-sterile products, with testing aligned to pharmacopeial standards such as United States Pharmacopeia (USP) <61>, USP <62>, and USP <71>.9

The study must demonstrate that the material remains within specification throughout the designated hold time. For microbiological testing, particular attention is given to sterile and non-sterile products (USP <61>, <62>, <71>).9

For example, in oral solid dosage forms, the granulation may be held before tableting. A study might evaluate moisture content, particle size, and potency over several days. For sterile products, bioburden levels and endotoxins must remain within limits during hold times before sterilization or filling.

An industry case study by Singh et al.10 found that failure to validate hold times was a common reason for regulatory observations, particularly in aseptic manufacturing. Therefore, documenting hold time data and incorporating them into the batch record is essential.

Aseptic Processing Solution Holding Time

In biologic manufacturing, aseptic processing solution (APS) or similarly termed intermediate solutions are often held for defined periods between processing steps. APS holding time refers to the duration for which a sterile or aseptic product, solution, or intermediate can be held under controlled conditions before the next processing step while maintaining its quality, safety, and efficacy.

APS holding time is crucial due to the sensitivity of biologic products, which often include proteins, mAbs, or vaccines that are prone to degradation, aggregation, or microbial contamination. The time between production steps must be validated to ensure product integrity is not compromised.

The following are key reasons for controlling holding time:

• Stability: Proteins may degrade or lose activity if held too long.12
• Sterility: Aseptic conditions must be preserved to avoid contamination.11
• Process consistency: Variability in holding time can introduce inconsistencies in yield or efficacy.5

Regulatory Expectations

The FDA and the EMA require manufacturers to validate maximum holding times for in-process materials. These validations ensure that the product remains within specified quality parameters.9,13 

For example, FDA’s Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing emphasizes holding times as critical process parameters.10 EMA’s Guideline on the Sterilization of the Medicinal Product, Active Substance, Excipient and Primary Container mandates documentation and validation of all holding steps.11

More specific regional requirements can be found in the World Health Organization’s (WHO) Annex 4 guidance on hold times.15

Manufacturers must justify and validate hold times to ensure no adverse impact on quality. Failure to justify hold times is a common inspection finding.

Standard Operating Procedure (SOP) - Example

Title: Determination and Control of APS Holding Time in Biologic Manufacturing
Document Number: SOP-BIO-APS-001
Effective Date: [Insert Date]
Version: 1.0
Department: Manufacturing Sciences & Technology (MSAT) / Quality Assurance (QA)
Approved by: [Insert Approver Name and Title]

References: 3,5,9,11,14

1. Purpose

This SOP defines the procedures for establishing, validating, and controlling the holding time of APS or in-process bulk intermediates in biologic drug substance manufacturing to ensure product quality, safety, and efficacy are maintained throughout the process.

2. Scope

This procedure applies to all intermediate biologic process solutions (e.g., clarified harvest, column eluates, pooled fractions) that are held prior to subsequent processing steps in GMP operations at [Facility Name].

3. Definitions

• APS: Any in-process biologic solution handled under aseptic conditions.
• Holding time: The maximum allowable duration during which APS is stored prior to the next processing step.
• Critical Process Parameter (CPP): A variable that must be controlled within predetermined limits to ensure product quality.

4. Responsibilities

5. Procedure

5.1 Identification of APS Holding Points

1. Identify all intermediate product hold steps from process flow diagrams (e.g., post-harvest, post-chromatography, pre-formulation).
2. Assign unique solution IDs and holding time control points in batch records.

5.2 Holding Time Study Design

1. Conduct holding time studies under worst-case conditions (e.g., maximum duration, temperature).
2. Define test intervals: 0 h (control), 12 h, 24 h, 48 h, and as applicable based on process risk.
3. Store material in validated containers under controlled environmental conditions (e.g., 2–8 °C for harvest; ambient for buffers).

5.3 Testing Parameters

5.4 Data Analysis

1. Compare results at each time point to time 0 (baseline).
2. Determine time point at which any parameter fails to meet acceptance criteria.
3. Set the validated holding time as the shortest time point where all criteria remain acceptable.

5.5 Documentation and Approval

1. Document all study data in a Holding Time Validation Report.
2. Submit report to quality assurance (QA) department for review and approval.
3. Update master batch record (MBR) to include validated holding times.

6. Change Control

Any changes to APS composition, container/closure system, or holding conditions (e.g., temperature, duration) require re-evaluation of the holding time study under a formal change control process.

7. Deviation Management

If a holding time is exceeded during routine production, treat as a deviation and assess potential product impact. QA disposition is required prior to further processing.

Example in Biopharmaceutical Manufacturing

Example 1: Monoclonal Antibody Production

Process step: Protein A chromatography eluate
Scenario:

• Eluate stored at 2–8 °C
• Hold time study conducted for 72 hours

Findings:

• Aggregates increased after 48 hours
• Acceptable limit set at 36 hours (with safety margin)

Example 2: Viral Inactivation Step

Process step: Low pH hold
Purpose: Virus clearance

• Required hold: ~60 minutes at pH 3.5
• Over-holding risk: protein degradation

This is a critical hold time, directly impacting safety and efficacy.

Example 3: Bulk Drug Substance Storage

Scenario:

• Bulk antibody stored frozen at −80 °C

Study outcome:

• Stable for 12 months
• At −20 °C → degradation observed after 3 months

Example 4: Clean Hold Time

Scenario:

• Stainless steel bioreactor cleaned and sterilized

Study:

• Swab testing over time

Result:

• Maximum clean hold time established at 72 hours before re-cleaning is required

Challenges in Hold Time Determination

Lack of universal standards

• No fixed rule (e.g., “24-hour rule” is informal and not universally valid)

Process complexity

• Multiple interacting hold steps (cumulative effects unclear)

Operational constraints

• Manufacturing schedules may force longer holds

Biological variability

• Different molecules behave differently

Emerging Considerations

• Continuous manufacturing reduces hold times
• Single-use systems change storage dynamics
• Advanced analytics (PAT) enable real-time monitoring
• Cell and gene therapies require extremely tight hold controls due to ultra-short stability windows

Key Takeaways

• Hold time defines how long materials can safely “wait” during manufacturing.
• It is critical in biopharma due to protein instability and contamination risks.
• Must be experimentally validated, not assumed.
• Applies to materials, intermediates, bulk product, and equipment.
• Regulatory agencies expect scientific justification and lifecycle management.

Conclusion

Hold time management is a fundamental part of biologics manufacturing. Total and in-process hold times must be scientifically justified and validated to ensure product quality. Regulatory bodies expect comprehensive documentation and data to support these durations.

Hold time studies are a critical component of pharmaceutical manufacturing control strategies. They ensure that product quality is maintained during pauses in processing and that the manufacturing process remains compliant with GMP regulations. A well-designed hold time study provides scientific justification for the defined time limits between process steps and supports a robust quality management system.

References

1. FDA. Process Validation: General Principles and Practices. FDA. 2011. Accessed June 23, 2026. https://www.fda.gov/files/drugs/published/Process-Validation--General-Principles-and-Practices.pdf
2. Annex 2: Manufacture of Biological active substances and Medicinal Products for Human Use. EudraLex, Volume 4 – EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use. European Commission. 2018. Accessed June 23, 2026. https://health.ec.europa.eu/document/download/380fdf24-8a1e-4f65-809b-e08d990d5f9e_en?filename=2018_annex2_en.pdf
3. Annex 15. EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, European Medicines Agency. 2015. Accessed June 23, 2026. https://health.ec.europa.eu/system/files/2016-11/2015-10_annex15_0.pdf
4. Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. ICH.2000. Accessed June 23, 2026. https://database.ich.org/sites/default/files/Q7%20Guideline.pdf
5. Q8(R2). Pharmaceutical Development. International Council for Harmonisation. ICH. 2009. Accessed June 23, 2026. https://database.ich.org/sites/default/files/Q8%28R2%29%20Guideline.pdf
6. Q1A(R2) Stability Testing of New Drug Substances and Products. ICH. February 2003. Accessed June 23, 2026. https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf
7. Technical Report No. 6, Process Validation: A Lifecycle Approach for the Biopharmaceutical Industry. PDA. 2026.
8. Q9(R1) Quality Risk Management. International Council for Harmonisation. ICH 2023. Accessed June 23, 2026. https://database.ich.org/sites/default/files/Q9_Guideline.pdf
9. USP <61>, <62>, <71>. United States Pharmacopeia–National Formulary. USP2024
10. Singh R, Sharma P, and Patel S. Hold time study in pharmaceutical industry: A review. International Journal of Pharmaceutical Sciences and Research, 2020 11(8), 1000-1008.
11. FDA. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice. U.S. Food and Drug Administration. 2004. Accessed June 23, 2026. https://www.fda.gov/media/71026/download
12. Carpenter J F and Manning M C. Rational design of stable lyophilized protein formulations: theory and practice. Pharmaceutical Biotechnology, 2002 13, 109-133.
13. EMA. Guideline on the sterilisation of the medicinal product, active substance, excipient and primary container. European Medicines Agency. 2017.
14. Shukla A A and Thömmes, J. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends in Biotechnology, 2010 28(5), 253–261.
15. Annex 4 General Guidance on Hold Times. WHO Technical Report Series No. 992. WHO. 2015. Accessed June 23, 2026.https://www.who.int/docs/default-source/medicines/norms-and-standards/guidelines/distribution/trs992-annex4.pdf.

About the Author

Robert Dream is managing director of HDR Company LLC.